Dr. Kopans criticizes me and others for being “unable to break free of doubts” about the efficacy of mammography and says those who suggest there is ambiguity in its benefit are using “unscientific data analyses” and “scientifically unsupportable” data that have “been manipulated to generate doubt.”
Dr. Kopans criticizes me and others for being “unable to break free of doubts” about the efficacy of mammography and says those who suggest there is ambiguity in its benefit are using “unscientific data analyses” and “scientifically unsupportable” data that have “been manipulated to generate doubt.”
Despite these assertions, there are credible questions about mammography. Just this year there have been a plethora of articles in various medical journals that highlight such potential downsides of screening mammography as overdiagnosis. As Dartmouth professor H. Gilbert Welch wrote in a British Medical Journal editorial this past July, overdiagnosis is a “vexing problem,” and causes some women to undergo unnecessary treatment. Welch, however, does not disparage mammography; instead, he writes, “Mammography is one of medicine's 'close calls'-a delicate balance between benefits and harms-where different people in the same situation might reasonably make different choices. Mammography undoubtedly helps some women but hurts others. No right answer exists; instead it is a personal choice.”
As I wrote in my April 2009 Diagnostic Imaging article, I believe there is sufficient, albeit not incontrovertible, evidence that mammography does reduce mortality from breast cancer, and that radiologists and other physicians should, after discussing both the pros and the cons of screening, encourage but not coerce women to undergo annual screening mammography. At the same time, however, acknowledging rather than denying the existence of controversies regarding mammography will assist the public at large to develop a realistic appraisal of mammography's role with regard to breast cancer.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
Assessing MACE Risk in Women: Can an Emerging Model with SPECT MPI Imaging Have an Impact?
December 9th 2024In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
Assessing MACE Risk in Women: Can an Emerging Model with SPECT MPI Imaging Have an Impact?
December 9th 2024In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).
2 Commerce Drive
Cranbury, NJ 08512